Multi-drug resistant (MDR) enteric bacteria are of increasing global concern. A clonal group, Escherichia coli sequence type (ST) 131, harbors both MDR and a deadly complement of virulence factors. Patients with an immunocompromised system are at high risk of infections with these E. coli and there is strong epidemiologic evidence that the human intestinal tract, as well as household pets, may be a reservoir. Here, we examine if phages are an effective treatment strategy against this clonal group in murine models of bacteremia that recapitulate clinical infections. Bacteriophages isolated from known E. coli reservoirs lyse a diverse array of MDR ST131 clinical isolates. Phage HP3 reduced E. coli levels and improved health scores for mice infected with two distinct ST131 strains. Efficacy was correlated to in vitro lysis ability by the infecting phage and the level of virulence of the E. coli strain. Importantly, it is also demonstrated that E. coli bacteremia initiated from translocation across the intestinal tract in an immunocompromised host is substantially reduced after phage treatment. This study demonstrates that phage, isolated from the environment and with little experimental manipulation, can be effective in combating even the most serious of infections by E. coli "superbugs".
Extraintestinal pathogenic E. coli or ExPEC are a broad E. coli pathotype that asymptomatically colonize the human and canine gastrointestinal tract but are capable of infecting sites distal to the intestine 1, 2 . An ExPEC clonal group, referred to as sequence type 131 (ST131), has emerged as a pandemic multidrug-resistant (MDR) pathogen capable of producing extended spectrum beta lactamases, is refractory to fluoroquinolones, and is widely distributed in the community and hospital settings [3] [4] [5] . In addition to carrying resistance elements, these strains also harbor a deadly compliment of virulence factors [6] [7] [8] . This single clonal group is now considered the predominant cause of all antibiotic resistant E. coli infections in the US, with this species now the most frequently isolated Gram-negative bacterium from the blood of adult patients with sepsis 9, 10 . Sepsis was associated with 6% of all deaths in the US during 1999-2014 and one fourth of these deaths attributed to infections originating from the urinary or gastrointestinal tract 9, 11 . With 750,000 sepsis cases occurring annually in the US alone, and at a cost of more than $20 billion per year, there is an unmet need for new and effective treatments to combat drug-resistant bacterial infections 12, 13 . One possible solution to this growing issue is to develop bacteriophages (phages), natural parasites of bacteria, as prophylactic or therapeutic agents to kill resistant strains 14 . Bacteriophages were first described by F. W. Twort in 1915 15 . Félix d'Herelle later characterized them as lytic agents, capable of self-amplification on a suitable bacterial host, and developed the idea for phage therapy as a way to control infections caused by bacteria 16, 17 . With the advent of antibiotics in the 1940s, the prospect of phage therapy was discarded in the West, but several Eastern European nations have successfully used this approach to treat a variety of bacterial infections [17] [18] [19] [20] . The rise of antibiotic resistance in several bacterial pathogens that cause serious infections in humans has reinvigorated
Results
Isolation of phage that kill ExPEC sequence type 131. Phages are ubiquitous in the environment.
Due to the epidemiologic link in the virulence factor composition between avian pathogenic E. coli (APEC) 2 , canine E. coli that are positive for pap (pyelonephritis-associated pili) 26 , and the known virulence factor profile of human ExPEC, some of which have been documented in these reservoirs 26 , we sought to identify lytic phage from these E. coli reservoirs (see Methods). Using either a well-characterized ExPEC strain (CP9) or the laboratory strain E. coli MG1665 as the host, each reservoir yielded multiple plaques upon plating. Plaques from both hosts were tested for lytic activity on a panel of drug resistant ST131 ExPEC isolates 27 with broad virulence properties and clinical origin. The three phage reservoirs produced phages collectively capable of lysing every strain. Distinct specificities were noted for each phage isolate. All reservoirs produced virus capable of infecting > 90% of the ExPEC strains except derivatives of φ HP7 which showed overall lower activity compared to φ HP3 (< 10%) (Fig. 1) . Interestingly, JJ1886 was resistant to all phage except CF5-1, CF5-2, and CF10, which only weakly killed this ExPEC. Only MVAST0167 was killed by every phage.
Phage characterization and morphological analysis. We sought to characterize some of these phages for the presence of toxins or lysogenic elements, their basic infection parameters, and examine their morphology for classification. We chose to first sequence phages HP3, EC1, and CF2 because they were each isolated from a different source, they each display quite distinct strain specificity for their host bacterium (Fig. 1) , and they are likely to be phages pursued for future studies. Phages were sequenced by applying a DNA library generated by ligation mediated-PCR (LM-PCR) to an illumina MiSeq platform (see Methods). Phage HP3 is 168,188 base (Table 1) . Interestingly, phage HP3 is highly similar to Shigella phage pSs-1 28 with approximately 96% homology between the two for ORFs present in both phages. Phage CF2 is highly similar to Salmonella phage BP63 (accession # NC_031250.1, 96% over shared ORFs). Phage EC1 is similar to Shigella phage SHSML-52-1 (98% identity, accession # KX130865.1). BLASTP searches were performed on predicted ORFs for a functional analysis and all virulence genes were searched using VirulenceFinder 29 . No virulence genes of known toxicity (viral or bacterial) or genes involved in lysogeny (e.g. lysogeny cassettes) were detected. Mitomycin C treatment of E. coli strain JJ2528 infected with phage HP3, using the method described for Zeng et al. 30 which in our hands induced lysogeny of lambda phage (10,000 PFU/mL) from E. coli MG1655, did not yield any phage, confirming that HP3 is a lytic phage (data not shown). In addition, no genes that encode resistance to known antibiotics, as assessed using ResFinder 31 , were identified in HP3, CF2, or EC1. Thus, it seems that these phages are void of any known lysogenic or toxic elements that would preclude their use in experimental studies of efficacy.
Along these lines, we measured the (i) adsorption rate, (ii) burst size, and (iii) plaque morphology and size for HP3 (Table 2 ). The mean adsorption rate constant was determined to be 5.63 × 10 −9 mL/min with 99.8% adsorbed during a 20 minute infection period. The mean burst size and latent period were determined to be 60 and 22.5 min, respectively. All plaques had a mean diameter of 0.5 mm and were clear. The morphological properties of the phages were determined by cryoelectron microscopy. φ HP3 ( Fig. 2A) contains a prolate icosahedral head (W 75 nm, L 101 nm) and a clearly discernible T-4 like tail (W 22 nm, L 106 nm). The base plate was visible and the tail fibers, when visible, were observed in both the extended and contracted position ( Fig. 2A,i and iv) . A small proportion of particles lacked DNA ( Fig. 2A,v) . φ CF2 contains a tail of similar dimensions but with oblique striations (W 17 nm, L 85 nm). Its thin head (W 46 nm) gives it an overall elongated appearance (Fig. 2B) . φ CF2's capsid was substantially prolate and the tail fibers were only visible in particles with the tail in the contracted position (Fig. 2B,ii and iv) . A small number of empty particles were observed with the DNA ejected (Fig. 2B,iii) or not properly packaged (Fig. 2B,v) . The particularly prolate capsid of φ CF2 is similar to some viruses of the family Siphoviridae
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. Phage EC1 was similar to φ HP3 in morphology (Fig. 2C ). All three phage displayed features consistent with the family Myoviridae. The ability of the tail to contract, diagnostic of Myoviridae 33 , is supported by the presence of a minority of virions with partially or fully contracted tail sheaths ( Fig. 2A,iii,B ,ii and C,v). The tail inner tube extends past the end of the tail sheath in those cases. Curvature in the tail is often seen in Siphoviridae, but was never observed in the phages imaged here.
Therapeutic efficacy of phage with activity towards ST131. ExPEC ST131 strains are drug resistant and comprise a significant worldwide burden of bloodstream infections. We therefore studied whether the phages isolated and characterized here display therapeutic efficacy in a systemic model of ExPEC bacteremia. Mice were infected with a virulent ST131 strain, JJ2528 (10 8 CFU), which is sensitive to φ HP3, via the intraperitoneal route. One hour later, the infected animals were treated with φ HP3 (10 9 PFU) and disease monitored after 18 hours (Fig. 3A) . Infected mice given φ HP3 were substantially healthier (mean score of 1) than infected groups that did not receive phage (mean score 3.5) (Fig. 3B) . Animals receiving φ HP3 demonstrated, on average, a 3-4 log reduction in the bacterial burden across all organs examined (Fig. 3C ). Phage were likewise recovered from these tissues (Fig. 3D) .
Next, we sought to explore the effectiveness of φ HP3 relative to two key parameters important for therapeutic phages; (i) specificity of the phage amongst various E. coli ST131 strains in the context of an infection and (ii) the virulence of the bacterial strain in relation to the efficacy of the phage in the mammalian, infected host. We Table 2 . Basic characterization of phage HP3. Characterization of phage HP3 includes calculated adsorption constant (K), percent phage adsorbed, burst size, latent period, plaque size and morphology. All experiments were performed using E. coli JJ2528 as host.
first tested the in vivo specificity of φ HP3 by examining its efficacy against two strains, JJ1901 and JJ2547, both of which demonstrate high virulence but variable susceptibility to this phage ( Fig. 1 ). Mice were infected as described in Fig. 3A and the health or bacterial levels in the liver, spleen, kidney, and lungs were measured. Mice infected with JJ1901 showed a similar course of disease and dissemination to organs as JJ2528, consistent with it being a virulent strain (Fig. 4A ,i-v). Similar to JJ2528, when infected with JJ1901 and then given a single dose of φ HP3, both the overall health scores as well as the levels of ExPEC in the tissues were markedly reduced (~3.5 logs) (Fig. 4A ,i-v). However, when animals were infected with strain JJ2547, another highly virulent ExPEC strain with similar health and dissemination parameters as JJ1901 but low sensitivity to φ HP3, phage treatment demonstrated a modest improvement in health scores and lowering of ExPEC levels (only ~1 log reduction), both of which were not statistically significant (Fig. 4B ,i-v). We next tested the therapeutic efficacy of φ HP3 towards a strain that is highly susceptible to this phage in culture (JJ2050, Fig. 1 ) but displays low intrinsic virulence in the murine model. As expected, strain JJ2050 did not induce significant disease (score of 1.2) or attain high levels of bacterial burden in the surveyed organs (~3 logs less than JJ1901) in this model (Fig. 4C ,i-v). Interestingly, despite being highly susceptible to φ HP3 in culture, infected animals treated with φ HP3 showed a non-significant reduction of only 1.25 logs of CFU in major organs, which is in contrast to the ~3-4 logs observed for strains JJ2528 and JJ1901. All three infections yielded abundant and similar levels of φ HP3 in the lungs, spleen, kidneys, and liver. The efficacy of phage in neutropenic hosts undergoing bacterial translocation. A significant proportion of E. coli bacteremia originates in immunocompromised individuals. These patient populations constitute a sizable fraction of cancer, HIV, organ transplant, or otherwise vulnerable individuals whose immune function is low. In particular, cancer patients receiving chemotherapy are at risk of developing neutropenia, a condition characterized by a severe decline in circulating immune cells 34 . Prophylactic antibiotic treatments are necessary for these patients to prevent life-threatening infections, but such treatments may eliminate protective flora while inducing resistance 35 . To determine if phage are effective in this clinical context, we utilized a mouse model of chemotherapy-induced neutropenia whereby ExPEC-colonized mice undergo translocation from the gastrointestinal tract to develop a deadly bacteremia 36 . Mice were gavaged with JJ2528 and the animals were treated on alternate days with the cancer chemotherapy drug cytoxan (to induce neutropenia and bacterial translocation) and then given φ HP3 (IP) (Fig. 5A) . Fecal CFU demonstrated both mouse groups were colonized by JJ2528 at equivalent levels (Fig. 5B) . Importantly, in mice treated with φ HP3, there was a reduction in bacterial CFU in the assessed organs compared to the untreated mice. The majority of the untreated mice had bacteria in their liver and kidneys, while with φ HP3 treatment, these organs showed a statistically significant (p = 0.03) (Fig. 5C,ii) , which correlated with this organ also having the most (2.5 logs greater) PFU of phage (Fig. 5D) . Interestingly, phage titers were detected in intestinal tissue although phage was administered parenterally (Fig. 5D ).
Discussion
Here, we report (i) the isolation of phages from avian and canine reservoirs, (ii) that all of the phages examined show morphological features consistent with being members of the Myoviridae, (iii) that they show broad lytic activity on a diverse array of multidrug-resistant ExPEC ST131 strains, (iv) that one of these isolates, φ HP3, is efficacious against two human isolates in an injectional model of ExPEC bacteremia, (v) that a high bacterial burden in vivo and the in vitro lytic efficiency correlate with efficacy during bacteremia, and finally (vi) that these phage are effective against ExPEC in a model of gut-derived bacteremia in the immunocompromised host. This work demonstrates that it is quite feasible to isolate lytic phage with variable specificity for ExPEC and that these phages can have therapeutic efficacy in models of ExPEC bacteremia.
The structurally characterized phages described in this report are similar to the family of Myoviridae. The Myoviridae encompass five genera of bacteriophages, including the well-characterized Mu and T4-like viruses 37, 38 . These phages include those with activity against two medically significant Gram-positive bacteria, including phage K which targets Staphylococci 39 and phage EJ-1 which kills Streptococci 40 . Also included in this family are phage that target Gram-negative bacteria, such as Pseudomonas and Klebsiella 41, 42 , as well as phage developed for the control of diarrheagenic bacteria such as E. coli O157:H7 43 . A recent paper described a bacteriophage from the Podoviridae family that could lyse O25b strains from ST131 and ST69 groups, and demonstrated some efficacy in infection models 44 . Work here describes three myophage isolates, as well as additional phage preparations from various environmental sources, that demonstrate broad lytic activity against a diverse sampling of ST131 ExPEC strains. Shared strain preference amongst viruses from two distinct environmental reservoirs may indicate that the ST131 ExPEC clonal group harbors a shared receptor that is recognized by these and related myophages, and that such phages are quite ubiquitous in the environment.
The crisis of lethal infections with multidrug-resistant gram negative bacteria is now being formally recognized by world leaders and health organizations [45] [46] [47] [48] [49] . It has its origin in (i) the overuse of antibiotics in the food and health industries 2 , (ii) the ability of E. coli to exchange genetic information, (iii) asymptomatic and chronic co-habitation in the gastrointestinal tract of human and domesticated hosts 1, 26 and (iv) medical treatments which make the human host susceptible to such infections, including cancer chemotherapy 34 . Chronic colonization and surface polysaccharide diversity makes universal vaccination against E. coli a challenge. The development of new antibiotics has not adequately kept pace with the rise of resistance, largely because antibiotic development is a lengthy process associated with sometimes prohibitive costs. Therapeutic phages have been suggested by many as a potential solution, in terms of both prophylaxis and treatment 50 . In addition to being considered safe for human use 51 , the rapid evolution of phage allows for either expansion or restriction of the bacterial host range in days with simple laboratory procedures [52] [53] [54] making it useful for clonal outbreak strains such as ST131 that emerge as dominant human pathogens 55 . Also, their lytic activity occurs by a different mechanism than killing by antibiotics and their selective pressure can lead to the emergence of bacterial populations that have re-acquired sensitivity to antibiotics [56] [57] [58] . Consistent with these ideas, we show here that suspected ExPEC reservoirs harbor phages that can efficiently kill clinically circulating and multi-drug resistant ST131 ExPEC. One of these viruses, φ HP3, demonstrates the ability to significantly improve the health of mice infected with two virulent ExPEC strains and thus can lower the bacterial load below the threshold of bacteria needed to lead to a deadly infection. φ HP3 can also circulate to major organ tissues, as evidenced by its high titers in liver, lung, spleen, and kidney and its appearance in the intestine when examined. The levels of ExPEC in these infections after a single dose of φ HP3 treatment reduced the circulating levels of ExPEC by about 10,000 fold, activity which correlated with in vitro lytic results observed in culture and/or on agar plates. φ HP3 demonstrated less efficient killing activity against strain JJ2547 in culture which correlated with a loss of ~1,000 fold killing potential in the treatment of mice infected with this strain. These findings indicate that the trends observed in vitro do reflect those in vivo; however, even a slight loss in activity can translate into a much greater loss in the context of a complex mammalian host. This complexity likely works against the infection optimum and amplifies subtle in vitro differences in mounting a productive and complete infection. Thus, it would seem reasonable to include as a part of the study of phage therapy a molecular understanding of the mammalian host factors that influence in vivo efficacy.
The propagation of phage in a mammalian host is bacterial density dependent 59, 60 . The density of bacteria may in turn be dependent on their intrinsic virulence; thus, more virulent ExPEC strains that invade the blood and grow to high levels may be more susceptible to phage. Indeed, we observed a correlation between ExPEC virulence and the phage's ability to reduce both health scores and bacterial burden. However, this creates a conundrum in that ExPEC that are less virulent but nevertheless a health concern may not be as responsive to phage. Infections with strains that do not produce robust bacteremia may require a combination treatment of antibiotics and phages or multiple treatments of phage over time. Combinatorial treatment with antibiotics can be beneficial by several different mechanisms. A resistance mutation to phage may be detrimental to the development of antibiotic resistance (or vice-versa), as strains are rarely resistant to both 61 . Also, these mutations could lead to fitness costs rendering them non-competitive in vivo 59 . Thus, it would seem that a comprehensive evaluation of phage therapy should also include the combinatorial use of phage and antibiotics, perhaps as a type of "adjuvant" to antibiotics.
Phage used to prevent or treat ExPEC infections is not without scientific and clinical barriers. The most serious obstacle is bacterial resistance to phage infection 62 . Prolonged (> 24 hours) incubation of ExPEC strain JJ2528 with φ HP3 did result in a low-level of bacterial cells that become resistant to lytic killing (data not shown). Another barrier to phage efficacy is the human immune system. The production of anti-phage antibodies in response to repeated dosage of phage over long periods is well-documented [63] [64] [65] . The antibody response to phage phiX174 is so robust that it is used to test immune responsiveness in humans 66 . Normal antibody responses to this antigen are consistently defective in patients with HIV 67 , genetic immunodeficiencies 68 and receiving immunosuppressing treatments 69 . In a clinical study of patients treated with phage therapy for bacterial infections, in which 50% of the patients were immunocompromised, 60% of patients given local administration of phage demonstrated low antibody neutralization in serum 70 . This is interesting because in our study we chose to test phage treatment of a bacterial infection within the context of immunosuppression, which is when patients are most at risk of these opportunistic ExPEC infections. The pronounced reduction of bacterial counts in all organs of treated mice in this model of bacterial translocation suggest phage therapy should be considered as one possible solution for these types of infections in high risk, immunocompromised patients. Such a therapy may prove useful in this patient population as there may be a reduction in circulating antibodies following phage treatment which would allow for repeated dosing and hence greater efficacy. Regardless, the fact that such efficient killers of ExPEC can be isolated and tested in such a short period of time indicates that phage should be considered an "adaptive drug", evolved in real-time to meet the specific needs of the problem at hand, thereby keeping pace with the rates at which resistance, or neutralization, arises.
Materials and Methods
Experimental Animals. The mouse strain BALB/c (Jackson laboratories, Bar Harbor, ME) was used for Bacterial Strains and Growth Conditions. ExPEC strain CP9 36 and MG1655 K12 were used as phage isolation strains. E. coli MG1655 (λ 16831) was used for the lysogeny assays. Figure 1 lists other E. coli strains (kindly provided by Dr. James Johnson, University of Minnesota) that were permissive for phage infection. All strains were grown in Lysogeny Broth (LB) at 37 °C from individual colonies selected on plates after resuscitation from a frozen stock (− 80 °C, 10% glycerol).
Phage Isolation and Plaque Assay. Geese, duck, and dog feces were collected from two parks (2 miles apart) in the Houston, Texas area. Chicken feces were collected from a private farm. Fecal samples were homogenized in phage buffer (1.0 M NaCl, 0.01 M Tris, pH 8.0, 0.001 M EDTA) by rocking gently using a benchtop rocker, separated by a Sorvall Lync 4000 Lynx centrifuge (Thermo Scientific, Waltham, Mass) at 13 K rpm (~29000 g, 50 min) and the supernatant filter sterilized (0.22 μ m). The filtrate was added to a soft agar overlay assay containing the isolation bacterial strain. Plaques of different morphology were selected, grown to high titer in the isolation strain and the lysates used to generate the efficiency of plating (EOP's) presented in Fig. 1 .
Phage Purification. Small batch cultures of CP9 for φ CF2 and JJ2547 for φ HP3 were grown to an O.D. of 0.1 at 600 nm, infected with phage lysate (MOI 0.1) until complete lysis was achieved and used to infect a large batch culture prepared in 4 Liters of LB. The lysate was centrifuged at 10 K RPM (~17000 g, 4 °C, 30 min) and precipitated with 30 g NaCl/1000 mL and 300 g of Polyethylene Glycol 8000. After overnight precipitation at 4 °C, the phage was pelleted at 10 K RPM (17000 g, 4 °C, 30 min) and then resuspended in 40 mL of phage buffer. One volume of CHCl 3 was added to the resuspended phage, emulsified, and phases separated by centrifugation, 10 K RPM (17000 g, 10 min). Cesium Chloride (CsCl) was added to the aqueous phase, treated with 5 μ g/ml DNAse/ RNAse mix for 30 minutes at 37 °C, adjusted to a density of 1.5 and ultracentrifuged using SW41 rotor (20 K RPM, 10 °C, 18 hrs). The phage band was collected and dialyzed in phage buffer (2000X Vol, twice).
Lysogeny testing.
A lysate consisting of φ HP3 was added (MOI 10) to stationary phase E. coli JJ2528 in an LB overlay assay. The next day, bacterial colonies insensitive to φ HP3 were isolated from these plates and were re-plated to remove residual phage. The induction of lysogens was tested using the method described for Zeng et al. 30 . Insensitive colonies from strains E. coli JJ2528 and E. coli MG1655 (λ 16831) were grown to log phase in LB. Cultures were incubated with the DNA damaging agent mitomycin C (10 μ g/ml, Fisher BioReagents, Waltham, Mass.) for two hours. Chloroform (2%) was added to the flasks to lyse cells. Lysed cultures were pelleted via centrifugation (7,000 × G, 10 minutes) and an aliquot removed and serially plated on a lawn of the originator strain. Other φ HP3 insensitive colonies, E. coli JJ2528 and E. coli MG1655 (λ 16831) were lysed after log phase growth and pelleted to plate for the spontaneous induction of phage.
Measurement of burst size and latent period. These procedures were based on the experiments of Ellis and Debruick 71 with some modifications 72 . An overnight culture of E. coli JJ2528 was grown to mid-log phase and purified φ HP3 was added at an MOI of 1. Phage was allowed to adsorb for 20 minutes with shaking (255 rpm, 37 °C). Following adsorption, the culture was pelleted via centrifugation (10,000 × G, 5 minutes). The pellet was washed and prewarmed LB media added to resuspend the pellet. The resuspended culture was grown as before (37 °C, 255 rpm) . Samples (100 μ L) were taken every 10 minutes after resuspension for 2 hours total. Samples were lysed (Chloroform 2-5%) and pelleted (8,000 × G, 5 minutes), supernatant aliquots were serially diluted and plated on a lawn of E. coli JJ2528. φ HP3 burst size was calculated as the final titer of the plateau period to the initial titer of infected bacteria 73 . The latent period was determined to be the interval when there was no or little increase in the titer 73 .
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Adsorption Assays. Adsorption was measured according to established methods 72 . Briefly, φ HP3 (MOI 1) was added to a mid-log phase culture of E. coli JJ2528. Immediately after addition of φ HP3, 100 μ l of culture was removed (time point "0"). This sample was added to 900 μ L of chilled LB media (choroform added) then vortexed and kept on ice. This was repeated with samples taken every minute for a total of 10 minutes. All samples were pelleted via centrifugation (8,000 × G, 5 minutes) and supernatant aliquots were serially diluted and plated on a lawn of JJ2528. An adsorption curve was generated using this data with the adsorption rate constant calculated as the natural log of the slope of the graph versus the bacterial titer 72 .
Bacteriophage sequencing and genome assembly. Phages HP3, EC1, and CF2 were grown to high titer and purified as described above. Phage DNA extraction, sequencing and assembly was done by the Center for Metagenomics and Microbiome Research (CMMR) at Baylor College of Medicine. Phage DNA was extracted using the Applied Biosystems MagMAX Viral DNA/RNA Isolation kit (Applied Biosystems, Foster City, CA) and eluted in 50 μ l of Elution Buffer. Extracted DNA samples were constructed into Illumina paired-end libraries. DNA from phages HP3, EC1, and CF2 were sheared into fragments of approximately 500-600 base pairs using a Covaris E210 system (Covaris, Inc. Woburn, MA). Products were then amplified through Ligation Mediated-PCR (LM-PCR), which was performed using the KAPA HiFi DNA Polymerase (Kapa Biosystems, Inc., Cat. no. KM2602). Purification was performed with Agencourt AMPure XP beads after each enzymatic reaction. Following the final XP bead purification, quantification and size distribution of the LM-PCR product was determined using the Agilent Bioanalyzer 7500 chip. The libraries had an average final size of 660 bp (including adapter and barcode) and were pooled in equimolar amounts to achieve a final concentration of 10 nM. The library templates were prepared for sequencing on an Illumina MiSeq. Briefly, this library was denatured with sodium hydroxide and diluted to 6 pM in hybridization buffer in order to achieve a load density of 670 K clusters/ mm2. The library pool was loaded on a MiSeq flow cell which was spiked with 1% phiX control library for run quality control. The sample then underwent bridge amplification to form clonal clusters, followed by hybridization with the sequencing primer. Sequencing runs were performed in paired-end mode using the 600V3 kit. Sequencing-by-synthesis reactions were extended for 301 cycles from each end, with an additional 10 cycles for the index read. After sequencing, the.bcl files were processed through Illumina's analysis software (CASAVA), which demultiplexes pooled samples and generates sequence reads and base-call confidence values (qualities). The average raw yield per sample was 3,064 Mbp. Raw data files were trimmed using Babraham Bioinformatics' TrimGalore script 74 , and then had human and PhiX removed using a combination of Bowtie 75 Cryo-electron Microscopy. Quantifoil grids of mesh size 400 (Quantifoil Micro Tools GmbH, Großlöbichau, Germany) were rendered hydrophilic by 20-25 s glow discharge, or in the case of phage CF2, by 5 s plasma discharge in a Solarus Model 950 (Gatan, Pleasanton, CA). Next, 3 μ L of phage were applied to the grid, blotted for 1-2.5 s, and vitrified in a Vitrobot Mk IV (FEI, Hillsboro, OR). Grids were imaged in JEOL 200 kV cryoelectron microscopes and images were recorded with a DE12 direct detection device (Direct Electron LP, San Diego, CA) or with a US4000 CCD (Gatan). To render figures, images were low-pass filtered to a resolution of 20 Å using EMAN2 82 . Feature lengths were measured manually in EMAN2 based on calibrated detector pixel sizes.
Murine Infections. All methods described below were approved in accordance with relevant guidelines and regulations by the Institutional Animal Care and Use Committee.
Injectional bacteremia model. Overnight bacterial cultures were grown to log phase at 37 °C (250 rpm). Cultures were washed twice in 1XPBS. Colony forming units (CFU) were determined by plating on bacteriologic agar and a dose of 10 8 CFU injected intraperitonealy (IP) 83 . After 1 hour, infected mice were injected with purified φ HP3, IP, with 10 9 plaque forming units -PFU in 100 μ l of PBS.
Translocation bacteremia model. This model system is described in detail in reference 36 . Briefly, mice were gavaged with 10 9 CFU of ExPEC strain JJ2528 and animals administered cyclophosphamide (Cytoxan, Baxter Healthcare Corporation, Deerfield, IL, USA) IP for a total dose 450 mg/kg body weight on days 1, 3 and 5 as indicated in Fig. 3 . Purified φ HP3 was administered IP on the days 2, 4 and 6 as indicated in Fig. 3 and the mice necropsied on day 7 post infection.
Measurement of health scores. The scale for measuring murine health is based on four scored parameters, including activity (lethargy), grooming behavior (rough coat), body condition (hunched posture), and respiratory distress (hypernea or labored breathing), as outlined by the NIH Animal Research Advisory Committee Guidelines for the evaluation of rodent health 84 . Each observation of one of these criteria during a 20 minute period receives a score of 0, 0.5 or 1 depending on the severity. Mice with respiratory distress receive a score of 0 for normal breathing or a score of 1 for labored breathing (hyperpnea). All other parameters receive either a 0 (no disease), 0.5 (moderate) or 1 (severe). The scoring is performed by a blinded investigator that is trained to Scientific RepoRts | 7:46151 | DOI: 10.1038/srep46151 recognize these symptoms. When animals reach a score of 4, they are considered moribund and must be sacrificed according to our protocol approved by our institutional review board.
Bacterial and phage quantification of organ and fecal homogenates. Immediately following euthanization mice were necropsied under sterile conditions. Lungs, kidneys, liver and spleen were weighed and homogenized in 1XPBS with sterile blades. Organ homogenates were serially diluted and plated on LB plates and incubated at 37 °C overnight. Phage counts were quantified using a soft agar overlay assay. Fecal counts were determined on LB and Ampicillin, 100 μ g/ml, plates to prevent growth of other commensal flora.
Statistics.
Statistical significance values were determined using "R" version 3.2.4. For Fig. 3 panel B, and Fig. 4 panels A-i ,B-i and C-i, a Wilcoxon rank sum test was used to assess significance. For Fig. 3 panel C, Fig. 4  panels A,ii-v,B ,ii-v and C,ii-v and Fig. 5 panels B and C a two-tailed T-test on normalized data (log transformed) was used to test significance. For Figs 3D, 4D and 5D a One-Way ANOVA test was performed on normalized data and Tukey's test for multiple comparison was used to determine significance. Unless otherwise noted, alpha values were set to 0.05 and statistical significance was determined if calculated P values were below 0.05. Figure  " n" values are reported in the legend under each figure. 
